Compounding Bill In Senate Adds Office Use Provisions
This article was originally published in The Pink Sheet Daily
Executive Summary
New version of compounding bill would allow compounders to produce limited supplies for office use, but schedule for Senate floor action remains to be seen.
You may also be interested in...
Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Generics Savings Once Again Could Help A Major US Health Care Reform Bill
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.